I just find the entire exchange hilarious. I have been invested in companies with about a dozen commercial launches and it is always the same thing. The company says it is too early and there is too much variability to give guidance (and rightly so). The first half dozen questions are all trying to elicit any tidbit of information to help ascertain a revenue estimate. It even gets to the point where the analysts themselves feel silly about the questions by saying "let me ask this another way" or "want to just ask another question about revenue". I just find it funny that it was so predictable.
Agree that by keeping it vague, if an individual investor can do better research (and I think that is possible in small cap biotechs), you can play the ER updates and other events as a catalyst. I put my first trade on way too early but put on another going into this one that should pay off nicely. Will see where we are and what the estimates are going into Q2 to see if there could be another upside pop.
News 
Market Data 
Discover 
